Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd. (KRX: 207940) is trading at ₩1,219,000.00, about ₹87,978 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 4.54% today. Samsung Biologics is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩1,218,000.00
Today's high
₩1,274,000.00
52 week low
₩1,218,000.00
52 week high
₩1,987,000.00
207940 opened at ₩1,273,000.00, closed previously at ₩1,277,000.00, and has traded between ₩1,218,000.00 and ₩1,987,000.00 over the past 52 weeks.
About
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Key statistics
Avg. volume
61.27K
Market cap
₩56.43T
P/E Ratio
28.42
Price-to-sales ratio
12.41
Enterprise value
₩79.16T
Free cash flow yield
1.09%
Debt-to-equity ratio
0.15
Return on equity
23.95%
ROIC
17.81%
Beta
0.19
Dividend yield
0.00%
Last dividend
₩0.00
Financial overview
Revenue
₩4.56T
Earnings per share
₩38,588.00
Free cash flow
₩856.07B
Net profit margin
43.64%
Gross margin
55.54%
EBITDA
₩2.78T
Revenue growth
30.31%
Similar securities
This is not an investment recommendation
Samsung Biologics for Indian investors
Samsung Biologics is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Samsung Biologics for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneSamsung Biologics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
FAQs
Can I buy Samsung Biologics on Paasa?
Samsung Biologics (207940) has been listed on the Korea Exchange since 2016, in the Biotechnology industry. Samsung Biologics is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Samsung Biologics share cost in rupees?
One Samsung Biologics share is ₩1,219,000.00 — about ₹87,978 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Samsung Biologics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Samsung Biologics shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Samsung Biologics price.
Does Samsung Biologics pay a dividend?
No. Samsung Biologics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one: dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Samsung Biologics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Samsung Biologics?
Yes. Samsung Biologics is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.